Erlotinib and Sequential Positron Emission Tomography (PET) in Advanced Non Small Cell Lung Cancer (NSCLC)

• Status: Unknown status
• Trial end date: 2009-12-01
• Target enrollment: 0
• Participant gender: All

Summary

This is a Phase-II Study to evaluate the accuracy of Fluorodeoxyglucose-/Fluorothymidine-Positron Emission Tomography (FDG-/FLT-PET) analyses for early prediction of non-progression in patients with non-small-cell lung cancer (NSCLC) treated with Erlotinib.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Lung Cancer Group Cologne
• Treatments: Erlotinib Hydrochloride

Criteria

Inclusion Criteria:

• Written informed consent

• ≥ 18 years of age

• Untreated non-small-cell lung cancer stage IIIB/IV

• Life expectancy > 3 months

• Performance status ECOG 0-2

Exclusion Criteria:

• Concurrent systemic immune therapy, chemotherapy or therapy with any anticancer drug not indicated in the study protocol

• Any investigational agent(s) within 4 weeks prior to study entry

• Previous administration of any EGFR-targeted therapy (antibodies, small molecules and others)

• Any medical, mental or psychological condition which in the opinion of the investigator would not permit the patient to complete the study or understand the patient information